Olon SpA:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Olon SpA - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10798
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イタリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Olon SpA (Olon), formerly Antibioticos SpA, a susbsidiary of P&R S.p.A. is a developer and producer of active pharmaceutical ingredients. The company offers products such as azacitidine, bezafibrate, ibuprofen sodium, acamprosate calcium, acebutolol hydrochloride, acitretin, thalidomide, abacavir sulfate, etretinate, doxorubicin hydrochloride, abiraterone acetate, rifampycin and pridinol mesylate, among others. Its products are used in the therapeutic areas such as muscle relaxant, antibacterial, anticholinergic, antibiotic, anti-parkinson, mucolitic, hepatoprotectant, diuretic, antiviral, antineoplastic, alcohol dependence treatment, bronchodilator, HIV proteinase inhibitor, anxiolytic, lipoprotein disorders and exclusive parenteral feeding. Olon also provides custom synthesis and contract manufacturing services. The company operates through its manufacturing facilities located in Italy and Spain. Olon is headquartered in Rodano, Italy.

Olon SpA – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Olon SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Olon SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Olon SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Olon SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Olon SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Olon SpA, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
Olon to Acquire API Manufacturing Facility from Novartis 10
Olon Acquires Chemical Division from Ricerca Biosciences 11
Private Equity 12
Main Market Partners Acquires Ricerca Biosciences 12
Asset Transactions 13
Olon Acquires Chemical Division from Ricerca Biosciences 13
WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 14
Salix Pharma Acquires Worldwide IP Rights To Amorphous Rifaximin From Olon 15
Eurofins Scientific Completes Acquisition Of Pan Labs Pharmacology Unit From Ricerca Biosciences 16
Acquisition 17
Frontage Laboratories Acquires Concord Biosciences 17
Olon to Acquire Infa Group 18
Olon SpA – Key Competitors 19
Olon SpA – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Research And Development 20
Jan 26, 2018: Olon Announces Investment and Expansion of APIs Manufacturing Capabilities 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Olon SpA, Pharmaceuticals & Healthcare, Key Facts 2
Olon SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Olon SpA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Olon SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Olon SpA, Deals By Therapy Area, 2012 to YTD 2018 8
Olon SpA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Olon to Acquire API Manufacturing Facility from Novartis 10
Olon Acquires Chemical Division from Ricerca Biosciences 11
Main Market Partners Acquires Ricerca Biosciences 12
Olon Acquires Chemical Division from Ricerca Biosciences 13
WIL Research Acquires Pharma Services Business Of Ricerca Biosciences 14
Salix Pharma Acquires Worldwide IP Rights To Amorphous Rifaximin From Olon 15
Eurofins Scientific Completes Acquisition Of Pan Labs Pharmacology Unit From Ricerca Biosciences 16
Frontage Laboratories Acquires Concord Biosciences 17
Olon to Acquire Infa Group 18
Olon SpA, Key Competitors 19
Olon SpA, Subsidiaries 19

List of Figures
Olon SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Olon SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Olon SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Olon SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Olon SpA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Olon SpA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Olon SpA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Olon SpA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Olon SpA:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • The Siam Cement Public Co Ltd:企業の戦略・SWOT・財務情報
    The Siam Cement Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary The Siam Cement Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Theraclion SA (ALTHE):医療機器:M&Aディール及び事業提携情報
    Summary Theraclion SA (Theraclion) is a medical device company that designs, markets, and develops high-intensity focused therapeutic ultrasound devices and equipment; and offers technical support services. The company offers echotherapy solution that combines HIFU therapy with ultrasound as a syste …
  • Leukemia & Lymphoma Society Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary The Leukemia & Lymphoma Society Inc (LLS) is a voluntary health organization that focuses on funding research for identifying cure for blood cancer. The organization also assures access to treatments for blood cancer patients. Its offers patient support, health education, policy advocacy, an …
  • Marksans Pharma Ltd (MARKSANS):企業の財務・戦略的SWOT分析
    Summary Marksans Pharma Ltd (Marksans Pharma) is a pharmaceutical company that develops, manufactures and markets branded formulations and generic products. The company manufactures non-sterile liquids, ointments and powder products. It offers solid oral dosage in form of tablets, hard gelatin capsu …
  • PulteGroup Inc (PHM):企業の財務・戦略的SWOT分析
    PulteGroup Inc (PHM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Toyota Industries Corporation:企業の戦略・SWOT・財務分析
    Toyota Industries Corporation - Strategy, SWOT and Corporate Finance Report Summary Toyota Industries Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • AES Gener SA (AESGENER):企業の財務・戦略的SWOT分析
    AES Gener SA (AESGENER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • The Royal Bank of Scotland Group Plc:企業のM&A・事業提携・投資動向
    The Royal Bank of Scotland Group Plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Royal Bank of Scotland Group Plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports …
  • AB Science SA (AB):企業の財務・戦略的SWOT分析
    Summary AB Science SA (ABS) is a pharmaceutical company focused on discovery, development, and commercialization of protein kinase inhibitors. The company's lead compound Masitinib, is a orally administered tyrosine kinase inhibitor targeting mast cells and selected kinases, including c-Kit, PDGFR, …
  • Dana Inc:企業の戦略・SWOT・財務分析
    Dana Inc - Strategy, SWOT and Corporate Finance Report Summary Dana Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Uniper SE (UN01):企業の財務・戦略的SWOT分析
    Uniper SE (UN01) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • University of California Los Angeles:医療機器:M&Aディール及び事業提携情報
    Summary University of California Los Angeles (UCLA) a subsidiary of University of California, is an educational service provider that offers undergraduate education, graduate, professional education and continuing education. The university’s services include support services, campus services, gradua …
  • Institut Curie-製薬・医療分野:企業M&A・提携分析
    Summary Institut Curie is a cancer research foundation that operates cancer research institutes and hospitals and concentrates on the developing new treatments for cancer. The foundation carries out research in the areas of immunology, pharmachemistry, bioinformatics and systems biology, cell biolog …
  • SGS SA (SGSN):企業の財務・戦略的SWOT分析
    SGS SA (SGSN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …
  • SternMaid GmbH & Co KG:企業の戦略・SWOT・財務情報
    SternMaid GmbH & Co KG - Strategy, SWOT and Corporate Finance Report Summary SternMaid GmbH & Co KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Banco Hipotecario SA (BHIP3):企業の財務・戦略的SWOT分析
    Banco Hipotecario SA (BHIP3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Schneider Electric SE (SU):電力:M&Aディール及び事業提携情報
    Summary Schneider Electric SE (Schneider Electric), formerly Schneider Electric SA, is an energy management and automation company that develops related technologies and solutions for electricity distribution. Its product line includes automation and control products, building management and securit …
  • Savola Group Co:戦略・SWOT・企業財務分析
    Savola Group Co - Strategy, SWOT and Corporate Finance Report Summary Savola Group Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Power Finance Corporation Ltd.:企業の戦略・SWOT・財務分析
    Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report Summary Power Finance Corporation Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Bank of Queensland Limited (BOQ):企業の財務・戦略的SWOT分析
    Bank of Queensland Limited (BOQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆